Logo Logo
Switch Language to German
Cohen, Stanley A.; Aloi, Marina; Arumugam, Ramalingam; Baker, Robert; Bax, Kevin; Kierkus, Jaroslaw; Koletzko, Sibylle; Lionetti, Paolo; Persson, Tore; Eklund, Stefan (2017): Enteric-coated budesonide for the induction and maintenance of remission of Crohn's disease in children. In: Current Medical Research and Opinion, Vol. 33, No. 7: pp. 1261-1268
Full text not available from 'Open Access LMU'.


Objective: These studies evaluated the safety and efficacy of enteric-coated budesonide for the induction and maintenance of remission of mild-to-moderate Crohn's disease (CD) in children. Methods: The consecutive, multicenter, open-label, non-comparative studies enrolled patients aged 6-17 years. In the induction study, patients with active CD of the ileum and/or ascending colon received budesonide 9mg or 6mg once daily for 8 weeks;in the maintenance study, patients in remission received budesonide 6mg once daily for 12 weeks. The primary objective was assessment of safety, including glucocorticosteroid-related side effects and serum cortisol levels. Efficacy was assessed using the Pediatric Crohn's Disease Activity Index (PCDAI), and health-related quality of life (HRQoL) using the IMPACT-III questionnaire. Results: In the induction study (n=108), most adverse events were related to CD, commonly abdominal pain;possible glucocorticosteroid-related effects included acne and increased appetite but without significant weight gain. Subnormal morning cortisol levels were observed in 32 of 103 patients after 8 weeks. Budesonide reduced disease activity from baseline (meanstandard deviation, 9.1 +/- 8.5 vs. 19.1 +/- 10.1, p<.001) with 58.1% of patients reaching remission (PCDAI <10);HRQoL improved (p<.001). In the maintenance study (n=50), mean disease activity worsened (p=.047) with HRQoL unchanged (p=.33). Conclusions: Budesonide treatment was generally well tolerated, although the potential for adrenal suppression was noted. Budesonide was effective for induction of remission in children with mild-to-moderate CD but not for maintaining remission (ClinicalTrials.gov identifiers: NCT01444092, NCT01453946).